NCT01070225 is a Phase 4 clinical trial of Hydrocortisone/ Placebo and Propranolol in Asthma, sponsored by University of Dundee.

Who is sponsoring NCT01070225?

NCT01070225 is sponsored by University of Dundee.

What drugs are being tested in NCT01070225?

Interventions in NCT01070225: Hydrocortisone/ Placebo and Propranolol.

Is NCT01070225 still recruiting?

NCT01070225 is currently completed. Last updated 10 April 2019.

Last reviewed 2019-04-10 · How we verify

NCT01070225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reversal of Acute β-Blocker Induced Bronchoconstriction

Completed Phase 4 Last updated 10 April 2019

What this trial tests

Phase 4 trial testing Hydrocortisone/ Placebo and Propranolol in Asthma in 14 participants. Completed in 1 October 2010.

Timeline

1 March 2010

Primary endpoint
1 August 2010

1 October 2010

Quick facts

Lead sponsor	University of Dundee
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	14
Start date	1 March 2010
Primary completion	1 August 2010
Estimated completion	1 October 2010
Sites	1 location across United Kingdom

Drugs / interventions tested

Hydrocortisone/ Placebo and Propranolol — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

University of Dundee

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To establish whether acute β-blockade influences the ability to achieve airway reversibility and recovery with systemic corticosteroids and nebulised bronchodilators following histamine challenge in mild to moderate asthmatics.
Time frame: 3 weeks

Sponsor's own description

Current therapies for the management of asthma include inhalers. Types of these medications (beta agonists), improve asthma symptoms by stimulating areas (receptors) within the human airway resulting in dilation of the human airway. Whilst these drugs are highly effectively in the immediate setting their longterm use, constantly stimulation of receptors within the airway has been associated with increased asthma exacerbations and rare cases of death. Conversely medications that block receptors within the human airway (betablockers)have been avoided in asthma. The main reason for this is because of the possible acute airway narrowing that can occur after soon after administration. However chronic use of betablockers in asthma has recently been shown to be of benefit in reducing airway inflammation which is of great importance in improving asthma control and reducing symptoms. Despite this early evidence supporting chronic use of beta blockers in asthma, there is concern in 2 major regards:their potential to cause acute airway narrowing (irrespective of longterm benefit) and the possibility that they could block the reliever action of beta agonists. The objective of this study is to establish how best to reverse the short term effects of a single dose of beta blocker. This study is designed as a single centre study, with participants attending the department on approximately 3 separate visits (including a screening visit) at approximately 1 weekly intervals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other University of Dundee trials

Trials by the same sponsor.

NCT06435156 — Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes · Phase 2 · recruiting
NCT05582798 — Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function · Phase 4 · completed
NCT04419805 — Single Palatal Temporary Anchorage Device for Anterior Open Bite · NA · unknown
NCT03747107 — Pharmacist and Data Driven Quality Improvement in Primary Care · completed
NCT04817332 — STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01070225 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Dundee
Last refreshed: 10 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01070225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing